Visalia Medical Clinic, Visalia, CA, USA.
University at Albany - State University of New York, Albany, NY, USA.
J Gen Intern Med. 2024 May;39(7):1127-1134. doi: 10.1007/s11606-023-08348-4. Epub 2023 Dec 15.
Home INR testing (patient self-testing) is feasible and effective for warfarin patients but little is known about real-world differences in outcomes for patients using PST versus laboratory-based INR monitoring.
To compare the safety/efficacy of patient self-testing of real-world warfarin therapy versus office/lab-based monitoring of therapy.
DESIGN/SETTING/PARTICIPANTS/EXPOSURE: A retrospective claims-based analysis of warfarin patients enrolled in the MarketScan® Commercial Claims and Encounters and Medicare databases between January 1, 2013, and March 30, 2020. Stratification was based on INR testing method: patient self-testing versus testing at physicians' offices/local laboratory. The probability of adverse events in each cohort was determined after adjusting for demographic and baseline clinical characteristics using a repeated measures analysis.
Rates of all adverse events: deep venous thrombosis, pulmonary embolism, bleeding, and stroke. A secondary outcome of interest was emergency department visits.
A total of 37,837 patients were included in the analysis: 1592 patients in the patient self-testing group and 36,245 in the office-based therapy group. After adjusting for demographic and baseline clinical characteristics, patients in the office-based group had statistically significantly higher rates of all adverse events (incidence rate ratio [IRR]=2.07, 95% CI [1.82, 2.36]), and specific adverse events including thromboembolism (IRR=4.38, 95% CI [3.29, 5.84]), major bleed (IRR=1.45, 95% CI [1.28, 1.64]), and stroke (IRR=1.30, 95% CI [1.05, 1.61]) than patients in the patient self-testing group. Office-based patients also had a statistically significant higher rate of emergency department visits than patient self-testing patients (IRR = 1.65, 95% CI [1.47, 1.84]).
CONCLUSIONS/RELEVANCE: This analysis of real-world claims data shows lower rates of stroke, thromboembolism, and major bleeding, as well as fewer emergency department visits, with patient self-testing compared to office-based/lab INR monitoring. Our finding that PST is safe and effective among current users suggests that more patients may benefit from its use.
家庭 INR 检测(患者自测)对华法林患者是可行且有效的,但对于使用 PST 与基于实验室的 INR 监测的患者在实际结果方面的差异知之甚少。
比较真实世界中患者自我检测华法林治疗与办公室/实验室监测治疗的安全性/疗效。
设计/设置/参与者/暴露:2013 年 1 月 1 日至 2020 年 3 月 30 日,基于 MarketScan®商业索赔和就诊数据库和 Medicare 数据库,对接受华法林治疗的患者进行回顾性基于索赔的分析。分层基于 INR 检测方法:患者自我检测与医生办公室/本地实验室检测。使用重复测量分析,根据人口统计学和基线临床特征调整后,确定每个队列中不良事件的概率。
所有不良事件(深静脉血栓形成、肺栓塞、出血和中风)的发生率。一个感兴趣的次要结果是急诊就诊。
共有 37837 名患者纳入分析:1592 名患者在患者自我检测组,36245 名患者在办公室治疗组。调整人口统计学和基线临床特征后,与办公室治疗组相比,办公室治疗组的所有不良事件发生率均显著更高(发生率比[IRR]=2.07,95%可信区间[CI] [1.82, 2.36]),并且特定不良事件包括血栓栓塞(IRR=4.38,95%CI [3.29, 5.84])、大出血(IRR=1.45,95%CI [1.28, 1.64])和中风(IRR=1.30,95%CI [1.05, 1.61])。与患者自我检测组相比,办公室治疗组的急诊就诊率也显著更高(IRR=1.65,95%CI [1.47, 1.84])。
结论/相关性:这项基于真实世界索赔数据的分析表明,与基于办公室/实验室的 INR 监测相比,患者自我检测的中风、血栓栓塞和大出血发生率较低,急诊就诊次数也较少。我们的发现表明,目前的使用者中 PST 是安全有效的,这表明更多的患者可能受益于其使用。